5-amino-1mq nnmt inhibitor obesity Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target Size:50mg NAD-H AOD-9604 (acetate) (Anti-obesity Drug

5-amino-1mq nnmt inhibitor obesity Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target Size:50mg NAD-H AOD-9604 (acetate) (Anti-obesity Drug

AOD-9604 (acetate) (Anti-obesity Drug 9604) | Cayman Chemical

Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded

NAD-H

Size:50mg

Current research priorities include large-scale studies to better understand the tissue-specific effects of NNMT inhibition and the temporal dynamics of metabolic reprogramming following treatment